Julie Brennan

Phosphodiesterase 10A Inhibitor Activity in Preclinical Models of the Positive, Cognitive, and Negative Symptoms of Schizophrenia

Steven M. Grauer, Virginia Pulito, Rachel L. Navarra et al. · Journal of Pharmacology and Experimental Therapeutics · 2009 · 265 citations

WAY-163909 [(7 bR,10 aR)-1,2,3,4,8,9,10,10 a-Octahydro-7 bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A Novel 5-Hydroxytryptamine 2C Receptor-Selective Agonist with Preclinical Antipsychotic-Like Activity

Karen L. Marquis, Annmarie L. Sabb, Sheree F. Logue et al. · Journal of Pharmacology and Experimental Therapeutics · 2006 · 145 citations

DSM-5 PTSD's symptom dimensions and relations with major depression's symptom dimensions in a primary care sample

Ateka A. Contractor, Tory A. Durham, Julie Brennan et al. · Psychiatry Research · 2013 · 122 citations · Full text

Psychological Co-morbidities, Psychopathology, Psychiatry +11

Antidepressant-like effects of the novel, selective, 5-HT2C receptor agonist WAY-163909 in rodents

Sharon Rosenzweig‐Lipson, Annmarie L. Sabb, Gary Stack et al. · Psychopharmacology · 2007 · 100 citations

Molecular Pharmacology, Psychiatry, Functional Selectivity +11

Negative allosteric modulation of metabotropic glutamate receptor 5 results in broad spectrum activity relevant to treatment resistant depression

Zoë A. Hughes, Sarah J. Neal Webb, Daniel L. Smith et al. · Neuropharmacology · 2012 · 85 citations

Psychiatry, Negative Allosteric Modulation, Treatment Resistant Depression +12